<DOC>
	<DOCNO>NCT03071757</DOCNO>
	<brief_summary>The primary purpose Phase 1 , open-label study evaluate safety , pharmacokinetics , preliminary efficacy ABBV-368 monotherapy combination nivolumab participant locally advance metastatic solid tumor . The study consist 2 part : ABBV-368 dose escalation ABBV-368 tumor-specific dose expansion ( non-small cell lung cancer [ NSCLC ] cohort head neck cancer cohort ) .</brief_summary>
	<brief_title>A Study Safety , Tolerability Pharmacokinetics ABBV-368 Single Agent Combination Subjects With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Participants must histologic cytology diagnosis know immunogenic solid tumor , describe Part 1 Dose Escalation Part 2 Cohort Expansion : Parts 1A 1B Dose Escalation : 1A : Subjects advance metastatic solid tumor exhaust standard treatment incurable disease may treatment naïve program cell death 1 ( PD1 ) / program cell deathligand 1 ( PDL1 ) target agent antiPD1/PDL1 agent approve . Additional tumor type approve PD1/PDL1 therapy may consider Sponsor 's discretion provide failed therapy past . 1B : Subjects approve PD1/PDL1 target agent treatmentnaïve PD1/PDL1 target agent ; subject currently PD1/PDL1 approve therapy diagnose immunogenic type tumor ( eligible tumor type discuss sponsor ) ; subject treat PD1/PDL1 target agent refractory agent . Part 2A 2B Cohort Expansion : Non Small Cell Lung Cancer ( NSCLC ) : Participants locally advance metastatic NSCLC fail platinumbased therapy PD1/PDL1 target agent . Participants know genomic tumor aberration approve targeted therapy disease progression therapy prior receive ABBV368 . Head Neck cohort : Participants recurrent squamous cell head neck carcinoma candidate curative treatment local systemic therapy , metastatic ( disseminate ) head neck squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx consider incurable local therapy . Tumor progression recurrence must occur within 6 month last dose platinum therapy . Participants must treatment naïve PD1/PDL1 target agent . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 2 . Subject must immunerelated Response Evaluation Criteria Solid Tumors ( irRECIST ) evaluable measurable disease PART 1 measurable disease per irRECIST PART 2 Adequate bone marrow , kidney liver function . Received anticancer therapy include chemotherapy , immunotherapy , radiation therapy , biologic , herbal therapy , investigational therapy within period 21 day prior first dose ABBV368 . Prior treatment OX40 target agent . know uncontrolled metastasis central nervous system ( CNS ) . History active autoimmune disorder condition compromise impair immune system . Active bacterial , fungal viral infection include hepatitis B ( HBV ) hepatitis C ( HCV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatocellular carcinoma ( HCC )</keyword>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Merkel cell carcinoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>Metastatic Solid Tumors</keyword>
	<keyword>Non-small cell lung cancer ( NSCLC )</keyword>
	<keyword>Small cell lung cancer ( SCLC )</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>